A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.

开始日期2022-12-27

申办/合作机构

Anthos Therapeutics, Inc.

NCT05171075

/ Recruiting临床3期

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

开始日期2022-09-27

申办/合作机构

Anthos Therapeutics, Inc.

NCT05171049

/ Recruiting临床3期

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE

This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

开始日期2022-05-05

申办/合作机构

Anthos Therapeutics, Inc.

100 项与 Abelacimab 相关的临床结果

登录后查看更多信息

100 项与 Abelacimab 相关的转化医学

登录后查看更多信息

100 项与 Abelacimab 相关的专利（医药）

登录后查看更多信息

项与 Abelacimab 相关的文献（医药）

2025-09-01·JOURNAL OF THROMBOSIS AND HAEMOSTASIS

DOAC–Stop reverses the anticoagulant effect of asundexian and milvexian

Article

作者: Fitzpatrick, Ella K ; Weitz, Jeffrey I ; Fredenburgh, James C

BACKGROUND:

Asundexian and milvexian are small-molecule factor (F)XIa inhibitors, whereas abelacimab is an antibody that binds FXI and blocks its activation and activity. All 3 FXI inhibitors are currently undergoing phase 3 evaluation. Similar to heparin and dabigatran, asundexian, milvexian, and abelacimab prolong the activated partial thromboplastin time (APTT) in a concentration-dependent manner. DOAC-Stop (DS) is an activated charcoal-based compound that adsorbs direct oral anticoagulants such as dabigatran, but not heparin, from plasma. It is unknown whether DS also neutralizes asundexian and milvexian.

OBJECTIVE:

This study aimed to determine whether DS reverses the prolongation of the APTT caused by asundexian or milvexian. Dabigatran was used as a positive control, while abelacimab and heparin served as negative controls.

METHODS:

The APTT in human plasma, with or without asundexian, milvexian, abelacimab, dabigatran, or heparin, was determined before and after DS treatment.

RESULTS:

As expected, all drugs produced concentration-dependent prolongation of the APTT. DS returned the APTT to baseline values with asundexian, milvexian, and dabigatran, but not with abelacimab or heparin. The APTT was prolonged in a more than additive manner with the combination of 2.5 μM milvexian and 0.125 U/mL heparin. However, DS reversed only the APTT prolongation induced by milvexian, but not that by heparin.

CONCLUSION:

DS reverses the effect of asundexian and milvexian on the APTT and distinguishes between the APTT effects of milvexian and heparin.

2025-08-05·CIRCULATION

Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial

Article

作者: Goodrich, Erica L. ; Bloomfield, Dan ; Wojakowski, Wojciech ; Murphy, Sabina A. ; Morrow, David A. ; Weitz, Jeffrey I. ; Patel, Siddharth M. ; Parkar, Sanobar ; Giugliano, Robert P. ; Goodman, Shaun G. ; Sabatine, Marc S. ; Kiss, Robert G. ; Ruff, Christian T. ; Joung, Boyoung ; Chen, Shih-Ann ; Hug, Bruce ; Al Said, Samer

BACKGROUND::

Combining antiplatelet therapy (APT) with conventional anticoagulants increases the risk of bleeding. In the AZALEA-TIMI 71 trial (Safety and Tolerability of Abelacimab [MAA868] vs Rivaroxaban in Patients With Atrial Fibrillation), the novel factor XI inhibitor abelacimab significantly reduced the risk of bleeding compared with rivaroxaban in patients with atrial fibrillation. Whether the safety of combination antithrombotic therapy differs in the context of factor XI inhibition has not been well characterized.

METHODS::

This prespecified analysis of AZALEA-TIMI 71, which randomized patients between March and December of 2021 to 1 of 2 subcutaneous monthly abelacimab doses (90 or 150 mg) or oral rivaroxaban (20 mg daily, dose reduced to 15 mg in patients with creatinine clearance ≤50 mL/min), stratified patients by planned use of concomitant APT. The primary composite end point of major or clinically relevant nonmajor bleeding and other safety and efficacy outcomes were examined by concomitant APT and randomized treatment.

RESULTS::

Of 1287 patients (44% female; median age 74 years [interquartile range, 69–78]), 318 (24.7%) were on APT at baseline with planned continuation (15.5% aspirin only, 7.5% P2Y 12 inhibitor only, and 1.6% dual APT). In the rivaroxaban arm, the rate of major or clinically relevant nonmajor bleeding was 10.6 per 100 patient-years with concomitant APT versus 7.7 per 100 patient-years without. In the abelacimab arms, the rates were 2.5 and 3.5 per 100 patient-years for the 90-mg and 150-mg doses, respectively, with concomitant APT and 2.7 and 3.1 per 100 patient-years without. Each abelacimab dose significantly reduced major or clinically relevant nonmajor bleeding compared with rivaroxaban, both in those with concomitant APT (adjusted hazard ratio, 0.26 [95% CI, 0.10–0.70] and 0.30 [95% CI, 0.12–0.74] for 90 mg and 150 mg of abelacimab, respectively, versus rivaroxaban) and in those without concomitant APT (adjusted hazard ratio, 0.34 [95% CI, 0.19–0.60] and 0.40 [95% CI, 0.23–0.68] for 90 mg and 150 mg of abelacimab, respectively; Pinteractions =0.56 and 0.60, respectively). Patients with concomitant APT tended to derive greater absolute risk reductions with abelacimab (8.1 and 7.1 for 90 mg and 150 mg of abelacimab, respectively, versus rivaroxaban) than those without concomitant APT (5.0 and 4.6, respectively).

CONCLUSIONS::

Inhibition of factor XI with abelacimab consistently reduced bleeding compared with rivaroxaban regardless of concomitant APT use, with greater absolute reductions in bleeding in those requiring concomitant APT. These data suggest that factor XI inhibition may be a safe anticoagulant option in patients with atrial fibrillation requiring concomitant APT.

REGISTRATION::

URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04755283.

2025-08-05·CIRCULATION

Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation Receiving Oral Antiplatelet Therapy: Definitely Safe, but How Effective?

Communications

作者: Steg, Philippe Gabriel ; Mesnier, Jules

124

项与 Abelacimab 相关的新闻（医药）

2025-08-18

·GlobeNewswire-Health Care

New Novartis ESC data highlights strength of cardiovascular portfolio

PRESS RELEASE Two VictORION studies will highlight Leqvio’s impact on patient quality of life, and as a cholesterol lowering monotherapyLp(a)FRONTIERS APHERESIS study will assess effect of pelacarsen on reducing need for lipoprotein apheresis – a cholesterol removal procedure similar to dialysisPARACHUTE-HF study will highlight the efficacy and safety of Entresto to treat heart failure with reduced ejection fraction due to chronic Chagas diseaseAdditional presentations will assess the safety of new pipeline asset abelacimab in atrial fibrillation Basel, August 18, 2025 – Novartis will present data from 19 abstracts across its cardiovascular portfolio at the 2025 European Society of Cardiology (ESC) Congress in Madrid from August 29 to September 1, 2025. “The latest data we are presenting at ESC will showcase how Novartis is pioneering groundbreaking treatments that can transform cardiovascular outcomes,” said Ruchira Glaser, M.D., Global Head, Cardiovascular, Renal and Metabolic Development Unit, Novartis. “With established treatments Entresto and Leqvio, we continue to explore new ways to improve patient care whilst also investigating broader populations who may benefit. With promising pipeline assets, pelacarsen and abelacimab, we are tackling areas of significant unmet need to address the myriad of factors that cause or worsen heart disease.” Key highlights of data accepted by ESC include: Medicine Presentation Title Presentation Details Pelacarsen Pelacarsen reduces the need for lipoprotein apheresis in patients with elevated lipoprotein(a) and cardiovascular disease: The Phase 3 Lp(a)FRONTIERS APHERESIS trial Station 12 (Research Gateway) Moderated ePoster August 29, 09:15-10:00 CEST Pelacarsen Association of elevated lipoprotein(a) with future major adverse cardiovascular events in recurrent ASCVD patients: analysis of a large US electronic health record database Station 2 (Research Gateway) Moderated ePoster August 30, 17:15 – 18:00 CEST Pelacarsen Economic burden of elevated lipoprotein(a) in secondary prevention of atherosclerotic cardiovascular disease cohort from England Discovery Pole (North Convention Centre) Poster August 29, 15:15 CEST Leqvio VICTORION-Difference study: Inclisiran-based strategy vs standard of care Madrid (Main Auditorium) Hot Line August 30, 17:00 CEST Leqvio VICTORION-Mono China: efficacy and safety of inclisiran as monotherapy in Chinese adults with low or moderate ASCVD risk and elevated LDL-C Discovery Pole (North Convention Centre) Poster August 29, 10:00 CEST Abelacimab Prior anticoagulation experience, bleeding risk, and safety of factor XI inhibition in atrial fibrillation: an analysis of AZALEA-TIMI 71 Science Box 3 (Research Gateway) Poster September 1, 14:30 CEST Abelacimab Renal function and factor XI inhibition in atrial fibrillation: a pre-specified analysis of AZALEA-TIMI 71 Science Box 3 (Research Gateway) Poster September 1, 15:00 CEST Entresto PARACHUTE-HF: Randomized trial comparing sacubitril/valsartan with enalapril in patients with HFrEF caused by chronic Chagas cardiomyopathy Madrid (Main Auditorium) Hot Line September 1, 8:15 CEST About Novartis in Cardiovascular DiseaseAt Novartis, our mission is to ensure no heart is lost too soon. We envision a world where preventable CV deaths are no longer part of our lives. We’re proud of the positive impact we’ve made over the past 40 years and remain dedicated to tackling the most challenging problems in CVD. Through cutting-edge science and technology, we are focusing on areas of high unmet need, including scaling our xRNA platform across multiple risk factors and pioneering breakthroughs for genetically driven CVD risk factors and common heart conditions, including atrial fibrillation. We also work with patients, healthcare professionals, and organizations around the world to improve CV care beyond medicine alone. Together, we can help people with CVD enjoy longer, healthier lives and more time with their loved ones. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. # # # Novartis Media RelationsE-mail: media.relations@novartis.com Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: investor.relations@novartis.com

临床3期AHA会议

2025-08-13

·医药笔记

诺华：BAFF-R抗体干燥综合征、ITP三期临床接连成功

▎Armstrong 2025年8月11日，诺华宣布BAFF-R抗体Ianalumab治疗干燥综合征的量项三期临床NEPTUNUS-1、NEPTUNUS-2均达到主要终点，疾病活动度显著改善。Ianalumab有望成为首款干燥综合征新药。 2025年8月12日，诺华公布Ianalumab用于经激素治疗失败原发免疫性血小板减少症（ITP）的三期临床VAYHIT2顶线数据，关键次要终点治疗6个月时血小板计数显著改善。诺华预计将在2027年与一线治疗VAHIT1的结果一起递交上市申请。 Ianalumab最初由Morphosys（2024年被诺华29亿美元收购）研发，Morphosys为抗体工程的先驱，有多款合作开发的抗体药物管线，包括诺华合作的BAFF-R抗体Ianalumab、Anthos合作的FXI抗体Abelacimab、Ultragenyx合作的硬骨素抗体Setrusumab、礼来合作的ACVR2B抗体Bimagrumab、HiBio及天境生物合作的CD38抗体Delzartamab等。 BAFF-R在成熟B细胞的存活中发挥着关键作用，为BAFF的主要受体之一，TACI则同时为BAFF、APRIL的受体。TACI靶点泰它西普已经成药，Atacicept、Povetacicept则在仅仅追赶。诺华Ianalumab则引领了BAFF-R的临床探索，直到如今在干燥综合征、ITP完成POC。总结除了干燥综合征、ITP，诺华围绕Ianalumab还在探索狼疮性肾炎、系统性红斑狼疮、化脓性汗腺炎、全身性硬皮病等多项自免适应症。诺华在自免领域积累深厚，引领了IL-17A抗体、BTK抑制剂、BAFF-R抗体、CAR-T等多个赛道的进展。 Armstrong技术全梳理系列 GPRC5D靶点全梳理； CD40靶点全梳理； CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向； Claudin 6靶点全梳理； Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇； CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理； Ambrx技术全梳理； Vir Biotech技术全梳理； Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理； Momenta技术全梳理； NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

临床3期免疫疗法细胞疗法抗体药物偶联物并购

2025-08-07

·BioSpace

Novartis Continues Hunt for New Assets With Rumored Takeover of RNA Specialist Avidity

iStock, beast01 There is no certainty that the buyout will come to pass, according to The Financial Times , which first reported the rumors. Novartis has approached rare disease-focused Avidity Biosciences with an acquisition offer, The Financial Times reported on Wednesday, citing anonymous sources familiar with the matter. There is no certainty that a deal will come to fruition, and other suitors could approach Avidity, the sources cautioned. Novartis has expressed its interest in Avidity in recent weeks, which noted that a buyout would likely be at a premium to Avidity’s market cap. As of market close Wednesday, Avidity was worth $5.82 billion . The biotech’s shares surged 26% on Wednesday after rumors of the Novartis takeover broke. Analysts at BMO Capital Markets, writing to investors Wednesday, called these buyout rumors “unconfirmed” but “reasonable.” Avidity is an attractive acquisition target for Novartis given the biotech’s “leadership in muscular RNAi therapies across” key neuromuscular indications “that could enable two first-in-disease . . . multi-billion dollar opportunities,” they added. Avidity’s clinical candidates “target high unmet need neuromuscular indications that lack disease-modifying treatments,” BMO said, noting that these assets also “enable significant commercial synergies among them.” Chief among these promising assets is the investigational antibody-oligonucleotide conjugate (AOC) delpacibart zotadirsen, also called del-zota, in development for the treatment of patients with Duchenne muscular dystrophy who are amenable to exon 44 skipping. Del-zota made it to BioSpace ’s list of the five most promising DMD assets to watch for this year. Phase I/II data showed that del-zota boosted dystrophin expression to 25% of normal levels. Last month, the FDA granted del-zota Breakthrough Therapy designation. Avidity at the time said that it remains “on track” to submit a Biologics License Application for the asset by the end of the year. The biotech also expects to be able to report topline Phase II data in the fourth quarter. Avidity is also developing del-desiran for myotonic dystrophy type 1 and del-brax for facioscapulohumeral muscular dystrophy. It also has a handful of preclinical programs running for a variety of other neuromuscular indications. For Novartis, the Avidity deal would continue the pharma’s deal-making spree in recent months. In June, for instance, the company signed a four-year pact with Flagship Pioneering’s startup ProFound Therapeutics, putting up to $750 million on the line per cardiovascular target that they work on. Details of the deal have been scant, however: The companies have not disclosed how many targets they are eyeing, nor have they named specific priority indications. In April, Novartis dropped $1.7 billion to acquire Regulus Therapeutics and its miRNA-targeting molecules. A few months earlier, in February, the pharma made a $3.1 billion bet to buy Anthos Therapeutics, the current owner of abelacimab, an anticoagulant antibody that Novartis previously owned.

并购寡核苷酸突破性疗法临床2期

100 项与 Abelacimab 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
全身性栓塞	临床3期	美国	Lonza AG	2022-12-27
全身性栓塞	临床3期	美国	Anthos Therapeutics, Inc.	2022-12-27
全身性栓塞	临床3期	日本	Anthos Therapeutics, Inc.	2022-12-27
全身性栓塞	临床3期	日本	Lonza AG	2022-12-27
全身性栓塞	临床3期	加拿大	Lonza AG	2022-12-27
全身性栓塞	临床3期	加拿大	Anthos Therapeutics, Inc.	2022-12-27
全身性栓塞	临床3期	以色列	Anthos Therapeutics, Inc.	2022-12-27
全身性栓塞	临床3期	以色列	Lonza AG	2022-12-27
心房颤动	临床3期	美国	Lonza AG	2022-12-27
心房颤动	临床3期	美国	Anthos Therapeutics, Inc.	2022-12-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04755283 (AZALEA-TIMI 71 \| AZALEA-TIMI 71, CTgov)	临床2期	脑卒中 \| 心房颤动	1,287	Abelacimab (Abelacimab 90 mg (MAA868))	廠廠齋淵鹹醖顧觸願鬱 = 淵糧觸憲簾範築廠網遞蓋繭鏇夢衊憲繭鏇艱餘 (淵夢壓夢壓廠製憲鹽夢, 艱壓艱糧膚窪齋醖遞憲 ~ 艱廠構襯製夢構窪醖繭) 更多	-	2025-07-30
				Abelacimab (Abelacimab 150 mg (MAA868))	廠廠齋淵鹹醖顧觸願鬱 = 網壓願衊壓選鑰餘觸鹹蓋繭鏇夢衊憲繭鏇艱餘 (淵夢壓夢壓廠製憲鹽夢, 襯網製鬱襯顧鹹壓蓋繭 ~ 鏇淵獵構築鹽憲獵夢選) 更多
NCT04755283 (AZALEA-TIMI 71, Company_Website) 人工标引	临床2期	出血 \| 心房颤动	-	abelacimab (≥75 years)	觸繭淵齋顧構製蓋鏇壓(鹽衊顧獵襯遞築獵鹽蓋) = 網獵衊顧鏇衊蓋鑰鑰糧壓鏇淵壓壓積觸艱糧觸 (選鬱構窪繭廠鏇觸鏇鹹 )	积极	2025-04-08
				abelacimab (＜75 years)	觸繭淵齋顧構製蓋鏇壓(鹽衊顧獵襯遞築獵鹽蓋) = 醖餘窪鹽鏇積繭衊築壓壓鏇淵壓壓積觸艱糧觸 (選鬱構窪繭廠鏇觸鏇鹹 )
NCT04755283 (AZALEA-TIMI 71, Pubmed) 人工标引	临床2期	心房颤动	1,287	Abelacimab 150 mgAbelacimab 150 mg	鑰簾鑰願願蓋襯醖衊積(窪鬱築鏇築齋繭網構顧) = 獵鏇憲願鹹淵積鑰鬱憲網範製艱觸齋鬱選憲願 (遞觸願窪遞窪齋壓積廠 )	积极	2025-01-23
				AbelacimabAbelacimab 90 mg	鑰簾鑰願願蓋襯醖衊積(窪鬱築鏇築齋繭網構顧) = 願獵齋獵構衊構鏇顧構網範製艱觸齋鬱選憲願 (遞觸願窪遞窪齋壓積廠 )
NCT04755283 (AZALEA-TIMI 71, GlobeNewswire) 人工标引	临床2期	血栓形成	-	Abelacimab 150 mg	夢齋積醖遞範糧繭廠構(積遞觸壓齋製願願夢餘) = 淵窪醖選構廠憲觸壓簾鬱網窪齋壓窪齋構網顧 (艱網醖膚衊襯範遞憲淵 )	积极	2024-11-16
				Rivaroxaban	夢齋積醖遞範糧繭廠構(積遞觸壓齋製願願夢餘) = 淵顧襯顧鏇願鬱壓遞廠鬱網窪齋壓窪齋構網顧 (艱網醖膚衊襯範遞憲淵 )
NCT04755283 (AZALEA-TIMI 71, PipelineReview) 人工标引	N/A	心房颤动	1,287	abelacimab 150 mg	構網窪積顧窪鏇構壓觸(遞鬱構鑰繭齋糧鑰觸鬱) = 餘醖繭餘構鹽憲衊鬱壓獵觸鏇襯遞遞觸艱顧醖 (鏇觸鑰網顧鑰蓋顧夢膚 ) 更多	积极	2023-11-13
				rivaroxaban 20 mg	-
NCT04755283 (AZALEA-TIMI 71 , Corporate Publications) 人工标引	临床2期	心房颤动	1,287	Abelacimab 150 mg	鬱艱鹽願積築鹹願夢膚(觸鹹壓糧鹽壓齋觸遞艱) = 遞遞製獵憲鏇顧選鬱鹹顧夢蓋襯衊構衊築鬱觸 (衊衊淵糧選餘齋顧鏇繭 ) 更多	优效	2023-11-12
				Rivaroxaban 20 mg	-
NCT04755283 (AZALEA-TIMI 71, Biospace) 人工标引	临床2期	心房颤动	1,287	Abelacimab	糧艱廠鹹築構憲襯襯淵(齋簾鏇壓膚觸簾製顧廠) = met 膚製衊鑰顧糧築衊顧襯 (夢繭觸餘製觸廠糧窪窪 ) 达到	积极	2023-09-18
				Rivaroxaban
NCT04213807 (CTgov)	临床2期	心房颤动	28	Placebo	夢築遞選願積鑰築簾鹹 = 範簾艱餘壓壓鏇襯襯襯齋鏇餘築鬱餘襯蓋夢簾 (蓋壓壓蓋餘廠蓋衊夢鹹, 顧蓋簾繭顧蓋齋襯鏇憲 ~ 餘觸糧蓋衊築膚餘淵憲) 更多	-	2021-12-07
EUCTR2019-003756-37-BG (ANT-005 TKA, ISTH2021 \| Company_Website) 人工标引	临床2期	静脉血栓栓塞	412	30mg abelacimab	築膚顧糧簾衊齋觸選遞(繭糧鏇築襯膚鹹鑰襯艱) = 鏇膚鬱衊繭鹹鹽鏇衊廠觸鹽廠鏇遞簾夢觸範襯 (遞簾壓醖廠衊構膚獵鬱 ) 更多	积极	2021-07-17
				75mg abelacimab	築膚顧糧簾衊齋觸選遞(繭糧鏇築襯膚鹹鑰襯艱) = 觸壓齋觸願夢夢鹹餘築觸鹽廠鏇遞簾夢觸範襯 (遞簾壓醖廠衊構膚獵鬱 ) 更多